Finepoint Capital LP Has $8.28 Million Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Finepoint Capital LP lifted its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 57.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,111,104 shares of the company’s stock after purchasing an additional 403,700 shares during the period. EyePoint Pharmaceuticals makes up about 0.5% of Finepoint Capital LP’s investment portfolio, making the stock its 17th biggest position. Finepoint Capital LP’s holdings in EyePoint Pharmaceuticals were worth $8,278,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS bought a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter worth $59,000. AlphaQuest LLC boosted its stake in shares of EyePoint Pharmaceuticals by 13,246.6% in the 4th quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock valued at $73,000 after purchasing an additional 9,670 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of EyePoint Pharmaceuticals during the 4th quarter worth approximately $76,000. China Universal Asset Management Co. Ltd. raised its stake in shares of EyePoint Pharmaceuticals by 40.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock worth $108,000 after buying an additional 4,179 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in EyePoint Pharmaceuticals by 22.4% during the 4th quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company’s stock worth $113,000 after acquiring an additional 2,782 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

Wall Street Analyst Weigh In

EYPT has been the topic of several analyst reports. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Chardan Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Finally, Citigroup assumed coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price target for the company. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to MarketBeat, EyePoint Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $26.63.

EyePoint Pharmaceuticals Stock Down 7.6 %

Shares of EYPT stock opened at $4.61 on Friday. The stock’s fifty day simple moving average is $6.47 and its 200 day simple moving average is $8.10. The firm has a market capitalization of $316.84 million, a P/E ratio of -2.31 and a beta of 1.41. EyePoint Pharmaceuticals, Inc. has a twelve month low of $4.51 and a twelve month high of $23.65.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. As a group, equities research analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.